Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors

Simone B.S.P. Terra, Hao Xie, Jennifer M. Boland, Aaron S. Mansfield, Julian R. Molina, Anja C. Roden

Research output: Contribution to journalArticle

Abstract

Loss of alpha thalassemia/mental retardation syndrome X-linked (ATRX), a chromatin regulator, is associated with worse prognosis in pancreatic neuroendocrine tumors. We investigated ATRX expression in pulmonary carcinoid tumors (PCT) and its diagnostic and prognostic role in these patients. Resected PCTs (1997-2017) were reviewed. Tumors were staged according to 8th UICC/AJCC system. ATRX nuclear expression was recorded independently by 2 reviewers. A cutoff of ≤5% of nuclear ATRX expression was statistically established as loss of expression. One-hundred-fifteen patients (72 women [63%]; median age of 60.5 years [interquartile range, 50.8-71.5]) harbored 69 (60%) typical and 46 (40%) atypical PCTs. Median tumor size was 2.3 cm (interquartile range, 1.6-3.8 cm). Loss of ATRX expression was associated with atypical PCTs (OR 7.4 [95% CI, 2.6-23, P <. 001]), when adjusted for lymphovascular invasion and perineural invasion. ATRX expression predicted atypical PCT with sensitivity of 37% (95% CI, 24%-52%), specificity of 92% (95% CI, 86%-98%), AUC of 0.62 (95% CI, 0.52-0.72). Loss of ATRX expression was associated with shorter disease-specific survival (HR = 11, 95% CI, 1.8-68, P =. 01), after adjusting for lymphovascular invasion and presence of metastatic disease at time of diagnosis. Interobserver agreement on ATRX expression by two reviewers was substantial (κ = 0.72 [95% CI, 0.60-0.80]). ATRX expression is more commonly lost in atypical than in typical PCT, and is associated with more aggressive tumor characteristics and shorter disease-specific survival.

Original languageEnglish (US)
Pages (from-to)78-85
Number of pages8
JournalHuman Pathology
Volume94
DOIs
StatePublished - Dec 2019

Fingerprint

Carcinoid Tumor
Lung
ATR-X syndrome
Neoplasms
Survival
Neuroendocrine Tumors
Chromatin
Area Under Curve

Keywords

  • ATRX
  • Carcinoid tumors
  • interobserver agreement
  • Pulmonary
  • survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. / Terra, Simone B.S.P.; Xie, Hao; Boland, Jennifer M.; Mansfield, Aaron S.; Molina, Julian R.; Roden, Anja C.

In: Human Pathology, Vol. 94, 12.2019, p. 78-85.

Research output: Contribution to journalArticle

Terra, Simone B.S.P. ; Xie, Hao ; Boland, Jennifer M. ; Mansfield, Aaron S. ; Molina, Julian R. ; Roden, Anja C. / Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. In: Human Pathology. 2019 ; Vol. 94. pp. 78-85.
@article{258b7aa1686b47df9b408b32bc404142,
title = "Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors",
abstract = "Loss of alpha thalassemia/mental retardation syndrome X-linked (ATRX), a chromatin regulator, is associated with worse prognosis in pancreatic neuroendocrine tumors. We investigated ATRX expression in pulmonary carcinoid tumors (PCT) and its diagnostic and prognostic role in these patients. Resected PCTs (1997-2017) were reviewed. Tumors were staged according to 8th UICC/AJCC system. ATRX nuclear expression was recorded independently by 2 reviewers. A cutoff of ≤5{\%} of nuclear ATRX expression was statistically established as loss of expression. One-hundred-fifteen patients (72 women [63{\%}]; median age of 60.5 years [interquartile range, 50.8-71.5]) harbored 69 (60{\%}) typical and 46 (40{\%}) atypical PCTs. Median tumor size was 2.3 cm (interquartile range, 1.6-3.8 cm). Loss of ATRX expression was associated with atypical PCTs (OR 7.4 [95{\%} CI, 2.6-23, P <. 001]), when adjusted for lymphovascular invasion and perineural invasion. ATRX expression predicted atypical PCT with sensitivity of 37{\%} (95{\%} CI, 24{\%}-52{\%}), specificity of 92{\%} (95{\%} CI, 86{\%}-98{\%}), AUC of 0.62 (95{\%} CI, 0.52-0.72). Loss of ATRX expression was associated with shorter disease-specific survival (HR = 11, 95{\%} CI, 1.8-68, P =. 01), after adjusting for lymphovascular invasion and presence of metastatic disease at time of diagnosis. Interobserver agreement on ATRX expression by two reviewers was substantial (κ = 0.72 [95{\%} CI, 0.60-0.80]). ATRX expression is more commonly lost in atypical than in typical PCT, and is associated with more aggressive tumor characteristics and shorter disease-specific survival.",
keywords = "ATRX, Carcinoid tumors, interobserver agreement, Pulmonary, survival",
author = "Terra, {Simone B.S.P.} and Hao Xie and Boland, {Jennifer M.} and Mansfield, {Aaron S.} and Molina, {Julian R.} and Roden, {Anja C.}",
year = "2019",
month = "12",
doi = "10.1016/j.humpath.2019.08.022",
language = "English (US)",
volume = "94",
pages = "78--85",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors

AU - Terra, Simone B.S.P.

AU - Xie, Hao

AU - Boland, Jennifer M.

AU - Mansfield, Aaron S.

AU - Molina, Julian R.

AU - Roden, Anja C.

PY - 2019/12

Y1 - 2019/12

N2 - Loss of alpha thalassemia/mental retardation syndrome X-linked (ATRX), a chromatin regulator, is associated with worse prognosis in pancreatic neuroendocrine tumors. We investigated ATRX expression in pulmonary carcinoid tumors (PCT) and its diagnostic and prognostic role in these patients. Resected PCTs (1997-2017) were reviewed. Tumors were staged according to 8th UICC/AJCC system. ATRX nuclear expression was recorded independently by 2 reviewers. A cutoff of ≤5% of nuclear ATRX expression was statistically established as loss of expression. One-hundred-fifteen patients (72 women [63%]; median age of 60.5 years [interquartile range, 50.8-71.5]) harbored 69 (60%) typical and 46 (40%) atypical PCTs. Median tumor size was 2.3 cm (interquartile range, 1.6-3.8 cm). Loss of ATRX expression was associated with atypical PCTs (OR 7.4 [95% CI, 2.6-23, P <. 001]), when adjusted for lymphovascular invasion and perineural invasion. ATRX expression predicted atypical PCT with sensitivity of 37% (95% CI, 24%-52%), specificity of 92% (95% CI, 86%-98%), AUC of 0.62 (95% CI, 0.52-0.72). Loss of ATRX expression was associated with shorter disease-specific survival (HR = 11, 95% CI, 1.8-68, P =. 01), after adjusting for lymphovascular invasion and presence of metastatic disease at time of diagnosis. Interobserver agreement on ATRX expression by two reviewers was substantial (κ = 0.72 [95% CI, 0.60-0.80]). ATRX expression is more commonly lost in atypical than in typical PCT, and is associated with more aggressive tumor characteristics and shorter disease-specific survival.

AB - Loss of alpha thalassemia/mental retardation syndrome X-linked (ATRX), a chromatin regulator, is associated with worse prognosis in pancreatic neuroendocrine tumors. We investigated ATRX expression in pulmonary carcinoid tumors (PCT) and its diagnostic and prognostic role in these patients. Resected PCTs (1997-2017) were reviewed. Tumors were staged according to 8th UICC/AJCC system. ATRX nuclear expression was recorded independently by 2 reviewers. A cutoff of ≤5% of nuclear ATRX expression was statistically established as loss of expression. One-hundred-fifteen patients (72 women [63%]; median age of 60.5 years [interquartile range, 50.8-71.5]) harbored 69 (60%) typical and 46 (40%) atypical PCTs. Median tumor size was 2.3 cm (interquartile range, 1.6-3.8 cm). Loss of ATRX expression was associated with atypical PCTs (OR 7.4 [95% CI, 2.6-23, P <. 001]), when adjusted for lymphovascular invasion and perineural invasion. ATRX expression predicted atypical PCT with sensitivity of 37% (95% CI, 24%-52%), specificity of 92% (95% CI, 86%-98%), AUC of 0.62 (95% CI, 0.52-0.72). Loss of ATRX expression was associated with shorter disease-specific survival (HR = 11, 95% CI, 1.8-68, P =. 01), after adjusting for lymphovascular invasion and presence of metastatic disease at time of diagnosis. Interobserver agreement on ATRX expression by two reviewers was substantial (κ = 0.72 [95% CI, 0.60-0.80]). ATRX expression is more commonly lost in atypical than in typical PCT, and is associated with more aggressive tumor characteristics and shorter disease-specific survival.

KW - ATRX

KW - Carcinoid tumors

KW - interobserver agreement

KW - Pulmonary

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85075501173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075501173&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2019.08.022

DO - 10.1016/j.humpath.2019.08.022

M3 - Article

C2 - 31499081

AN - SCOPUS:85075501173

VL - 94

SP - 78

EP - 85

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -